Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function in Vivo

Circulation

Volumn 132, Issue 7, 2015, Pages 567-577

  Glynn, Patric ^a,b   Musa, Hassan ^a,c   Wu, Xiangqiong ^a,b   Unudurthi, Sathya D ^a,b   Little, Sean ^a,c   Qian, Lan ^a,b   Wright, Patrick J ^a,c   Radwanski, Przemyslaw B ^a,c,d   Gyorke, Sandor ^a,c   Mohler, Peter J ^a,c   Hund, Thomas J ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b Ohio State University   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

action potential; arrhythmias, cardiac; calcium calmodulin dependent protein kinase type 2; ion channels; Na+ current

Indexed keywords

SODIUM CHANNEL NAV1.5; SPECTRIN; ACETANILIDE DERIVATIVE; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; PHOSPHOSERINE; PIPERAZINE DERIVATIVE; RANOLAZINE; SCN5A PROTEIN, MOUSE; SODIUM; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL DURATION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CALCIUM CELL LEVEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENOTYPE; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; IN VIVO STUDY; MALE; MEMBRANE POTENTIAL; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SODIUM CURRENT; STEADY STATE; ACTION POTENTIAL; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CHANNEL GATING; CHEMISTRY; GENE TARGETING; GENETICS; HEART VENTRICLE REMODELING; LIGATION; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; CONSTRICTION; GENE KNOCK-IN TECHNIQUES; ION CHANNEL GATING; MALE; MICE; MICE, INBRED C57BL; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PHOSPHORYLATION; PHOSPHOSERINE; PIPERAZINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANOLAZINE; SODIUM; SODIUM CHANNEL BLOCKERS; VENTRICULAR REMODELING;

EID: 84939531656     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.015218     Document Type: Article

References (50)

1. Abriel H, Kass RS., Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc Med 2005 15 35 40. doi: 10.1016/j.tcm.2005.01.001
2. Hund TJ, Mohler PJ., Nav channel complex heterogeneity: new targets for the treatment of arrhythmia? Circulation 2014 130 132 134. doi: 10.1161/CIRCULATIONAHA.114.010867
3. Maltsev VA, Sabbah HN, Higgins RS, Silverman N, Lesch M, Undrovinas AI., Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998 98 2545 2552
4. Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L., The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol 2014 221 137 168. doi: 10.1007/978-3-642-41588-3-7
5. Shryock JC, Song Y, Rajamani S, Antzelevitch C, Belardinelli L., The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res 2013 99 600 611. doi: 10.1093/cvr/cvt145
6. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, Danner BC, Sag CM, Hund TJ, Mohler PJ, Belardinelli L, Hasenfuss G, Maier LS, Sossalla S., Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol 2013 61 111 122. doi: 10.1016/j.yjmcc.2013.03.021
7. Undrovinas AI, Maltsev VA, Sabbah HN., Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 1999 55 494 505
8. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, Kamp TJ, Makielski JC., Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005 38 475 483. doi: 10.1016/j.yjmcc.2004.12.012
9. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A., Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2013 127 575 584. doi: 10.1161/CIRCULATIONAHA.112.134932
10. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G., Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004 110 904 910. doi: 10.1161/01.CIR.0000139333.83620.5D
11. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E., Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007 116 1647 1652. doi: 10.1161/CIRCULATIONAHA.107.724880
12. Song Y, Shryock JC, Wu L, Belardinelli L., Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004 44 192 199
13. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS., Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008 45 32 43. doi: 10.1016/j.yjmcc.2008.03.006
14. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN., Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006 17 suppl 1) S169 S177. doi: 10.1111/j.1540-8167.2006.00401.x
15. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C., Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007 116 1449 1457. doi: 10.1161/CIRCULATIONAHA.107.704890
16. Sicouri S, Glass A, Belardinelli L, Antzelevitch C., Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008 5 1019 1026. doi: 10.1016/j.hrthm.2008.03.018
17. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F., The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008 8 175 181
18. Miles RH, Passman R, Murdock DK., Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011 108 673 676. doi: 10.1016/j.amjcard.2011.04.017
19. Maier LS., Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms! Eur J Heart Fail 2012 14 1313 1315. doi: 10.1093/eurjhf/hfs168
20. Makielski JC, Valdivia CR., Ranolazine and late cardiac sodium current-a therapeutic target for angina, arrhythmia and more? Br J Pharmacol 2006 148 4 6. doi: 10.1038/sj.bjp.0706713
21. Maltsev VA, Reznikov V, Undrovinas NA, Sabbah HN, Undrovinas A., Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. Am J Physiol Heart Circ Physiol 2008 294 H1597 H1608. doi: 10.1152/ajpheart.00484.2007
22. Koval OM, Snyder JS, Wolf RM, Pavlovicz RE, Glynn P, Curran J, Leymaster ND, Dun W, Wright PJ, Cardona N, Qian L, Mitchell CC, Boyden PA, Binkley PF, Li C, Anderson ME, Mohler PJ, Hund TJ., Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. Circulation 2012 126 2084 2094. doi: 10.1161/CIRCULATIONAHA.112.105320
23. Xie LH, Chen F, Karagueuzian HS, Weiss JN., Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res 2009 104 79 86. doi: 10.1161/CIRCRESAHA.108.183475
24. Swaminathan PD, Purohit A, Hund TJ, Anderson ME., Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res 2012 110 1661 1677. doi: 10.1161/CIRCRESAHA.111.243956
25. Wagner S, Dybkova N, Rasenack EC, Jacobshagen C, Fabritz L, Kirchhof P, Maier SK, Zhang T, Hasenfuss G, Brown JH, Bers DM, Maier LS., Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest 2006 116 3127 3138. doi: 10.1172/JCI26620
26. Hund TJ, Koval OM, Li J, Wright PJ, Qian L, Snyder JS, Gudmundsson H, Kline CF, Davidson NP, Cardona N, Rasband MN, Anderson ME, Mohler PJ., A β(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. J Clin Invest 2010 120 3508 3519. doi: 10.1172/JCI43621
27. Aiba T, Hesketh GG, Liu T, Carlisle R, Villa-Abrille MC, O'Rourke B, Akar FG, Tomaselli GF., Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res 2010 85 454 463. doi: 10.1093/cvr/cvp324
28. Ma J, Luo A, Wu L, Wan W, Zhang P, Ren Z, Zhang S, Qian C, Shryock JC, Belardinelli L., Calmodulin kinase II and protein kinase C mediate the effect of increased intracellular calcium to augment late sodium current in rabbit ventricular myocytes. Am J Physiol Cell Physiol 2012 302 C1141 C1151. doi: 10.1152/ajpcell.00374.2011
29. Ashpole NM, Herren AW, Ginsburg KS, Brogan JD, Johnson DE, Cummins TR, Bers DM, Hudmon A., Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites. J Biol Chem 2012 287 19856 19869. doi: 10.1074/jbc.M111.322537
30. Marionneau C, Lichti CF, Lindenbaum P, Charpentier F, Nerbonne JM, Townsend RR, Mérot J., Mass spectrometry-based identification of native cardiac Nav1.5 channel α subunit phosphorylation sites. J Proteome Res 2012 11 5994 6007. doi: 10.1021/pr300702c
31. Hund TJ, Snyder JS, Wu X, Glynn P, Koval OM, Onal B, Leymaster ND, Unudurthi SD, Curran J, Camardo C, Wright PJ, Binkley PF, Anderson ME, Mohler PJ., β(IV)-Spectrin regulates TREK-1 membrane targeting in the heart. Cardiovasc Res 2014 102 166 175. doi: 10.1093/cvr/cvu008
32. Gudmundsson H, Curran J, Kashef F, Snyder JS, Smith SA, Vargas-Pinto P, Bonilla IM, Weiss RM, Anderson ME, Binkley P, Felder RB, Carnes CA, Band H, Hund TJ, Mohler PJ., Differential regulation of EHD3 in human and mammalian heart failure. J Mol Cell Cardiol 2012 52 1183 1190. doi: 10.1016/j.yjmcc.2012.02.008
33. Makara MA, Curran J, Little SC, Musa H, Polina I, Smith SA, Wright PJ, Unudurthi SD, Snyder J, Bennett V, Hund TJ, Mohler PJ., Ankyrin-G coordinates intercalated disc signaling platform to regulate cardiac excitability in vivo. Circ Res 2014 115 929 938. doi: 10.1161/CIRCRESAHA.115.305154
34. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, Luo A, Bers DM, Shryock JC, Belardinelli L., Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation 2011 123 1713 1720. doi: 10.1161/CIRCULATIONAHA.110.000661
35. Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, Bers D, Brown JH, Heller Brown J., Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 2009 119 1230 1240. doi: 10.1172/JCI38022
36. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, Maier LS, Olson EN., The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A 2009 106 2342 2347. doi: 10.1073/pnas.0813013106
37. Kreusser MM, Lehmann LH, Keranov S, Hoting MO, Oehl U, Kohlhaas M, Reil JC, Neumann K, Schneider MD, Hill JA, Dobrev D, Maack C, Maier LS, Gröne HJ, Katus HA, Olson EN, Backs J., Cardiac CaM Kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation 2014 130 1262 1273. doi: 10.1161/CIRCULATIONAHA.114.006185
38. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH., The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 2003 92 912 919. doi: 10.1161/01.RES.0000069686.31472.C5
39. Frommeyer G, Milberg P, Maier LS, Eckardt L., Late sodium current inhibition: the most promising antiarrhythmic principle in the near future? Curr Med Chem 2014 21 1271 1280
40. The CAST Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 321 406 412
41. DeGrande S, Nixon D, Koval O, Curran JW, Wright P, Wang Q, Kashef F, Chiang D, Li N, Wehrens XH, Anderson ME, Hund TJ, Mohler PJ., CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome. Heart Rhythm 2012 9 2034 2041. doi: 10.1016/j.hrthm.2012.08.026
42. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG., Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 2011 50 214 222. doi: 10.1016/j.yjmcc.2010.10.001
43. Thiel WH, Chen B, Hund TJ, Koval OM, Purohit A, Song LS, Mohler PJ, Anderson ME., Proarrhythmic defects in Timothy syndrome require calmodulin kinase II. Circulation 2008 118 2225 2234. doi: 10.1161/CIRCULATIONAHA.108.788067
44. Pellicena P, Schulman H., CaMKII inhibitors: from research tools to therapeutic agents. Front Pharmacol 2014 5 21. doi: 10.3389/fphar.2014.00021
45. Veldkamp MW, Viswanathan PC, Bezzina C, Baartscheer A, Wilde AA, Balser JR., Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ Res 2000 86 E91 E97
46. Marionneau C, Abriel H., Regulation of the cardiac Na channel Nav1.5 by post-translational modifications. J Mol Cell Cardiol 2015 82 36 47
47. Herren AW, Weber DM, Rigor RR, Margulies KB, Phinney BS, Bers DM., CaMKII Phosphorylation of NaV1.5: novel in vitro sites identified by mass spectrometry and reduced S516 phosphorylation in human heart failure. J Proteome Res 2015 14 2298 2311. doi: 10.1021/acs.jproteome.5b00107
48. van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers DM, Wehrens XH., Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 2010 122 2669 2679. doi: 10.1161/CIRCULATIONAHA.110.982298
49. Respress JL, van Oort RJ, Li N, Rolim N, Dixit SS, deAlmeida A, Voigt N, Lawrence WS, Skapura DG, Skårdal K, Wisløff U, Wieland T, Ai X, Pogwizd SM, Dobrev D, Wehrens XH., Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 2012 110 1474 1483. doi: 10.1161/CIRCRESAHA.112.268094
50. Nerbonne JM., Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms? Trends Cardiovasc Med 2004 14 83 93. doi: 10.1016/j.tcm.2003.12.006